LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali
Fattaey, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on
Monday, Sept. 25, 2017, at 3:35 p.m. EDT in New York.
A corresponding webcast of the presentation can be accessed by visiting: http://wsw.com/webcast/cantor6/cris.
The webcast will be archived shortly after the live event and available for 90 days following the conference, and also available
on the Investor Relations section of the Curis website at www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates
for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical
studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1
and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including
CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis
is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including
idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
jdentzer@curis.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
